1. Home
  2. VTYX vs GAUZ Comparison

VTYX vs GAUZ Comparison

Compare VTYX & GAUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTYX
  • GAUZ
  • Stock Information
  • Founded
  • VTYX 2018
  • GAUZ 2009
  • Country
  • VTYX United States
  • GAUZ Israel
  • Employees
  • VTYX N/A
  • GAUZ N/A
  • Industry
  • VTYX Medicinal Chemicals and Botanical Products
  • GAUZ Industrial Machinery/Components
  • Sector
  • VTYX Health Care
  • GAUZ Miscellaneous
  • Exchange
  • VTYX Nasdaq
  • GAUZ Nasdaq
  • Market Cap
  • VTYX 154.9M
  • GAUZ 152.3M
  • IPO Year
  • VTYX 2021
  • GAUZ 2024
  • Fundamental
  • Price
  • VTYX $2.79
  • GAUZ $6.64
  • Analyst Decision
  • VTYX Buy
  • GAUZ Strong Buy
  • Analyst Count
  • VTYX 4
  • GAUZ 3
  • Target Price
  • VTYX $11.33
  • GAUZ $14.67
  • AVG Volume (30 Days)
  • VTYX 2.0M
  • GAUZ 481.2K
  • Earning Date
  • VTYX 08-07-2025
  • GAUZ 08-07-2025
  • Dividend Yield
  • VTYX N/A
  • GAUZ N/A
  • EPS Growth
  • VTYX N/A
  • GAUZ N/A
  • EPS
  • VTYX N/A
  • GAUZ N/A
  • Revenue
  • VTYX N/A
  • GAUZ $101,165,000.00
  • Revenue This Year
  • VTYX N/A
  • GAUZ $28.49
  • Revenue Next Year
  • VTYX N/A
  • GAUZ $47.77
  • P/E Ratio
  • VTYX N/A
  • GAUZ N/A
  • Revenue Growth
  • VTYX N/A
  • GAUZ 18.63
  • 52 Week Low
  • VTYX $0.78
  • GAUZ $5.50
  • 52 Week High
  • VTYX $3.39
  • GAUZ $13.00
  • Technical
  • Relative Strength Index (RSI)
  • VTYX 62.76
  • GAUZ N/A
  • Support Level
  • VTYX $1.95
  • GAUZ N/A
  • Resistance Level
  • VTYX $2.51
  • GAUZ N/A
  • Average True Range (ATR)
  • VTYX 0.17
  • GAUZ 0.00
  • MACD
  • VTYX -0.02
  • GAUZ 0.00
  • Stochastic Oscillator
  • VTYX 104.37
  • GAUZ 0.00

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

Share on Social Networks: